Daniel Gaudet
Impact in
- Surgery top 0.05%
- Lipoproteins and Cardiovascular Health
- Cholesterol and Lipid Metabolism
-
- Lipid metabolism and disorders
Papers in
-
- Lipid metabolism and disorders 146
- Blood Pressure and Hypertension Studies 23
- Surgery 210
- Lipoproteins and Cardiovascular Health 197
- Co-authors
- Diane Brisson (114 shared papers)Marie‐Claude Vohl (41 shared papers)Jean Bergeron (66 shared papers)John J.P. Kastelein (36 shared papers)Claude Gagné (38 shared papers)Evan A. Stein (18 shared papers)Thomas Jay Hudson (21 shared papers)Jean‐Pierre Després (33 shared papers)
- Journals
- Journal of clinical lipidology (54 papers)Atherosclerosis (52 papers)Journal of the American College of Cardiology (19 papers)New England Journal of Medicine (16 papers)Diabetes (14 papers)
- Partner nations
- CanadaUnited StatesNetherlands
In The Last Decade
Daniel Gaudet
446 papers receiving 27.7k citations
Daniel Gaudet's Hit Papers
Peers
Comparison fields: 5 of 162
- Surgery 11.7k
- Cardiology and Cardiovascular Medicine 5.5k
- Endocrinology, Diabetes and Metabolism 3k
- Genetics 4.2k
- Molecular Biology 3.3k
Countries citing papers authored by Daniel Gaudet
This map shows the geographic impact of Daniel Gaudet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Gaudet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Gaudet more than expected).
Fields of papers citing papers by Daniel Gaudet
This network shows the impact of papers produced by Daniel Gaudet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Gaudet. The network helps show where Daniel Gaudet may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Gaudet, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 469 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes Hit paper breakdown → | 2000 | 1453 |
| 2 | Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Hit paper breakdown → | 2018 | 1445 |
| 3 | Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia Hit paper breakdown → | 2008 | 995 |
| 4 | Hypertriglyceridemic Waist Hit paper breakdown → | 2000 | 784 |
| 5 | Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2010 | 780 |
| 6 | Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society Hit paper breakdown → | 2021 | 655 |
| 7 | Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease Hit paper breakdown → | 2001 | 653 |
| 8 | PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2014 | 644 |
| 9 | Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Hit paper breakdown → | 2012 | 610 |
| 10 | Evinacumab for Homozygous Familial Hypercholesterolemia Hit paper breakdown → | 2020 | 607 |
| 11 | Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome Hit paper breakdown → | 2019 | 508 |
| 12 | Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Hit paper breakdown → | 2012 | 501 |
| 13 | 2008 | 465 | |
| 14 | Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia Hit paper breakdown → | 2015 | 452 |
| 15 | Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease Hit paper breakdown → | 2022 | 435 |
| 16 | Targeting APOC3 in the Familial Chylomicronemia Syndrome Hit paper breakdown → | 2014 | 424 |
| 17 | 2002 | 390 | |
| 18 | Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance Hit paper breakdown → | 2019 | 346 |
| 19 | 2012 | 340 | |
| 20 | ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia Hit paper breakdown → | 2017 | 277 |
About Daniel Gaudet
Daniel Gaudet is a scholar working on Cardiology and Cardiovascular Medicine, Surgery, Genetics, Endocrinology, Diabetes and Metabolism and Pediatrics, Perinatology and Child Health, having authored 469 papers that have together received 28.9k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (197 papers), Lipid metabolism and disorders (146 papers), Genetic Associations and Epidemiology (55 papers), Blood Pressure and Hypertension Studies (23 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (17 papers), Epigenetics and DNA Methylation (16 papers), Adipokines, Inflammation, and Metabolic Diseases (15 papers) and Birth, Development, and Health (14 papers). The work is most often cited by research in Surgery (11.7k citations), Cardiology and Cardiovascular Medicine (5.5k citations), Endocrinology, Diabetes and Metabolism (3k citations), Genetics (4.2k citations) and Molecular Biology (3.3k citations). Daniel Gaudet has collaborated with scholars based in Canada, United States and Netherlands. Frequent co-authors include Diane Brisson, Marie‐Claude Vohl, Jean Bergeron, John J.P. Kastelein, Claude Gagné, Evan A. Stein, Thomas Jay Hudson, Jean‐Pierre Després, Erik S. G. Stroes and Joel N. Hirschhorn. Their work appears in journals such as Journal of clinical lipidology, Atherosclerosis, Journal of the American College of Cardiology, New England Journal of Medicine and Diabetes.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.